Astrazeneca Ab

Cyrus Ohnmacht

Bruce Thomas Dembofsky

Ashokkumar Bhikkappa Shenvi

Peter Robert Bernstein

Keith Russell

Christopher Becker

Robert Toms Jacobs

Marc Chapdelaine

Hui-Fang Chang

Jeffrey Albert

James Woods

Thomas Richard Simpson

James Rosamond

James Kang

Robert Frank Dedinas

Compounds having the formula (I) pharmaceutical compositions containing them and their methods of use for the treatment of neurological disorders related to amyloid &#x3b2; protein production and neurological disorders such as Alzheimer's disease. These compounds inhibit &#x3b3; secretase and thereby inhibit the production of amyloid &#x3b2; protein, thereby acting to prevent the formation of neurological deposits of amyloid protein.

Lactams and uses thereof

This invention relates to novel compounds having the structural formula I below: and their pharmaceutically acceptable salts, tautomers or in vivo-hydrolysable precursors, compositions and methods of use thereof. These novel compounds provide a treatment or prophylaxis of anxiety disorders, cognitive disorders, and/or mood disorders.

Compounds and uses thereof

Compounds having the formula (I) pharmaceutical compositions containing them and their methods of use for the treatment of neurological disorders related to amyloid &#x3b2; protein production and neurological disorders such as Alzheimer's disease. These compounds inhibit &#x3b3; secretase and thereby inhibit the production of amyloid &#x3b2; protein, thereby acting to prevent the formation of neurological deposits of amyloid protein. 

The present application relates to internally cyclized naphthamide compounds of the formula Ia (wherein R, R, R, R, R, R, R, R, R, R, X, X, Y, Z, and n are as defined herein), which are useful, for example, for antagonizing the pharmacological actions of the neurokinin 1 (NK) receptor. In particular, these compounds are useful in the treatment of diseases in which Substance P is involved such as, for example, major depressive disorder, severe anxiety disorders, stress disorders, major depressive disorder with anxiety, eating disorders, bipolar disorder, substance use disorder, schizophrenic disorders, psychotic disorders, movement disorders, cognitive disorders, depression and/or anxiety, mania or hypomania, aggressive behaviour, obesity, rheumatoid arthritis, Alzheimer's disease, cancer, oedema, allergic rhinitis, inflammation, pain, gastrointestinal-hypermotility, Huntington's disease, chronic obstructive pulmonary disorder (COPD), hypertension, migraine, bladder hypermotility, and urticaria.

Neurokinin antagonists for use as medicaments

Compounds having the general formulawherein R, R, R, R, R, R, R, R, R, R, X, X, Y, Z and n are as defined in the specification, methods of using such compounds for the treatment of diseases and pharmaceutical composition comprising such compounds.

Naphthalenecarboxamides as tachykinin receptor antagonists

Compounds of formula (I), wherein R is a 5,6,7,8-tetrahydronaphth-1-yl group which may be substituted (the remaining groups defined herein), and pharmaceutical compositions containing the compounds and methods of using the compounds in the treatment of a condition where antagonism of the NK1 and/or NK2 receptors is beneficial.

N-(2-phenyl-4-piperidinybutyl)-5,6,7,8-tetrahydro-1-naphthalenecarboxamides and their use as neurokinin 1 (NK1) and/or neurokinin 2 (NK2) receptor antagonists

Growing community of inventors

Wilmington, DE, United States of America

Cyrus Ohnmacht